440103-32-2

Upstream product

• 752259-55-5 (2s,3aR,6aS)-2-[3-(cyclopentyloxy)-4-methoxyphenyl]-5-(1,3-dithian-2-ylidene)octahydropentalene-2-carbonitrile 
• 828919-96-6 [(1R,2S)-2-Carboxymethyl-4-cyano-4-(3-cyclopentyloxy-4-methoxy-phenyl)-cyclopentyl]-acetic acid 
• 752259-54-4 dimethyl 2,2'-[(1R,2S)-4-cyano-4-[3-(cyclopentyloxy)-4-methoxyphenyl]cyclopentane-1,2-diyl]diacetate 
• 439919-54-7 (2s,3aR,6aS)-2-[3-(cyclopentyloxy)-4-methoxyphenyl]-5-oxooctahydropentalene-2-carbonitrile 
• 828919-77-3 (3S,4R)-1-(3-Cyclopentyloxy-4-methoxy-phenyl)-3,4-bis-(2-oxo-ethyl)-cyclopentanecarbonitrile 
• 752259-53-3 (3aR,7aS)-2-[3-(cyclopentyloxy)-4-methoxyphenyl]-2,3,3a,4,7,7a-hexahydro-1H-indene-2-carbonitrile 
• 440103-33-3 methyl (2s,3aR,5r,6aS)-5-cyano-5-[3-(cyclopentyloxy)-4-methoxyphenyl]octahydropentalene-2-carboxylate 

Downstream Products

• 828919-04-6 (2S,3aS,5R,6aR)-5-Cyano-5-(3-cyclopentyloxy-4-methoxy-phenyl)-octahydro-pentalene-2-carboxylic acid (1-methoxy-1-methyl-ethoxy)-amide 

Relevant academic research and scientific papers

Orally active PDE4 inhibitor with therapeutic potential

Based on the promising results obtained by the clinical trial of Ariflo, further optimization of the spatial arrangement of the three pharmacophores (the carboxylic acid moiety, nitrile moiety and 3-cyclopentyloxy-4-methoxyphenyl moiety) in the

Orally active PDE4 inhibitors with therapeutic potential

Based on the successful results in the clinical trial of Ariflo, further optimization of the spatial arrangement of the three pharmacophores (carboxylic acid moiety, nitrile moiety and 3-cyclopentyl-4-methoxyphenyl moiety) in the structure of Ariflo 1 was